IBRX – ImmunityBio, Inc.
IBRX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
36.72
Margin Of Safety %
Put/Call OI Ratio
0.34
EPS Next Q Diff
0.03
EPS Last/This Y
0.12
EPS This/Next Y
0.41
Price
8.11
Target Price
14.4
Analyst Recom
1
Performance Q
23.78
Upside
-466.4%
Beta
0.09
Ticker: IBRX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-13 | IBRX | 7.29 | 0.38 | 0.38 | 688087 |
| 2026-04-14 | IBRX | 7.59 | 0.38 | 0.34 | 691673 |
| 2026-04-15 | IBRX | 7.8 | 0.37 | 0.09 | 695022 |
| 2026-04-16 | IBRX | 7.24 | 0.37 | 0.62 | 704445 |
| 2026-04-17 | IBRX | 7.8 | 0.38 | 0.20 | 715019 |
| 2026-04-20 | IBRX | 8.19 | 0.34 | 0.14 | 577650 |
| 2026-04-21 | IBRX | 8.1 | 0.33 | 0.33 | 594311 |
| 2026-04-22 | IBRX | 8.09 | 0.34 | 0.32 | 602003 |
| 2026-04-23 | IBRX | 8.2 | 0.34 | 0.09 | 604585 |
| 2026-04-24 | IBRX | 7.45 | 0.33 | 0.32 | 619031 |
| 2026-04-27 | IBRX | 7.3 | 0.34 | 0.36 | 610966 |
| 2026-04-28 | IBRX | 6.97 | 0.35 | 0.29 | 622202 |
| 2026-04-29 | IBRX | 6.97 | 0.35 | 0.35 | 625842 |
| 2026-04-30 | IBRX | 7.09 | 0.35 | 0.40 | 627975 |
| 2026-05-01 | IBRX | 7.1 | 0.35 | 0.27 | 629736 |
| 2026-05-04 | IBRX | 7.43 | 0.35 | 0.22 | 613475 |
| 2026-05-05 | IBRX | 7.59 | 0.35 | 0.13 | 625027 |
| 2026-05-06 | IBRX | 8.38 | 0.35 | 0.23 | 628417 |
| 2026-05-07 | IBRX | 7.76 | 0.35 | 0.14 | 638650 |
| 2026-05-08 | IBRX | 8.5 | 0.34 | 0.09 | 650791 |
| 2026-05-11 | IBRX | 8.1 | 0.33 | 0.18 | 656262 |
| 2026-05-12 | IBRX | 8.11 | 0.34 | 0.23 | 672730 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-13 | IBRX | 7.29 | 53.3 | -25.0 | -0.25 |
| 2026-04-14 | IBRX | 7.60 | 53.3 | -35.0 | -0.25 |
| 2026-04-15 | IBRX | 7.80 | 53.3 | -31.3 | -0.25 |
| 2026-04-16 | IBRX | 7.24 | 53.3 | -7.1 | -0.25 |
| 2026-04-17 | IBRX | 7.68 | 53.3 | -39.7 | -0.25 |
| 2026-04-20 | IBRX | 8.19 | 53.3 | -41.7 | -0.25 |
| 2026-04-21 | IBRX | 8.10 | 53.3 | -21.8 | -0.25 |
| 2026-04-22 | IBRX | 8.09 | 53.3 | -24.0 | -0.25 |
| 2026-04-23 | IBRX | 8.20 | 53.3 | -28.4 | -0.25 |
| 2026-04-24 | IBRX | 7.45 | 53.3 | -1.2 | -0.25 |
| 2026-04-27 | IBRX | 7.30 | 53.3 | -19.5 | -0.25 |
| 2026-04-28 | IBRX | 6.97 | 53.3 | -13.6 | -0.25 |
| 2026-04-30 | IBRX | 7.09 | 53.3 | -28.8 | -0.25 |
| 2026-05-01 | IBRX | 7.09 | 53.3 | -24.4 | -0.25 |
| 2026-05-04 | IBRX | 7.44 | 53.3 | -37.1 | -0.25 |
| 2026-05-05 | IBRX | 7.59 | 53.3 | -30.1 | -0.25 |
| 2026-05-06 | IBRX | 8.39 | 53.3 | -51.4 | -0.25 |
| 2026-05-07 | IBRX | 7.75 | 53.3 | -5.4 | -0.25 |
| 2026-05-08 | IBRX | 8.51 | 53.3 | -47.1 | -0.25 |
| 2026-05-11 | IBRX | 8.11 | 53.3 | 490.7 | -0.25 |
| 2026-05-12 | IBRX | 8.11 | 40.0 | 478.6 | -0.26 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-14 | IBRX | -0.07 | 7.35 | 39.32 |
| 2026-04-15 | IBRX | -0.07 | 7.35 | 39.32 |
| 2026-04-16 | IBRX | -0.07 | 7.35 | 39.32 |
| 2026-04-17 | IBRX | -0.07 | 7.35 | 39.32 |
| 2026-04-20 | IBRX | -0.07 | 7.41 | 39.32 |
| 2026-04-21 | IBRX | -0.07 | 7.41 | 39.32 |
| 2026-04-22 | IBRX | -0.07 | 7.41 | 36.71 |
| 2026-04-23 | IBRX | -0.08 | 7.41 | 36.71 |
| 2026-04-24 | IBRX | -0.08 | 7.41 | 36.71 |
| 2026-04-27 | IBRX | -0.08 | 7.65 | 38.01 |
| 2026-04-28 | IBRX | -0.08 | 7.65 | 38.01 |
| 2026-04-29 | IBRX | -0.08 | 7.65 | 38.01 |
| 2026-04-30 | IBRX | -0.08 | 7.65 | 38.01 |
| 2026-05-01 | IBRX | -0.08 | 7.65 | 38.01 |
| 2026-05-04 | IBRX | -0.08 | 6.08 | 38.01 |
| 2026-05-05 | IBRX | -0.08 | 6.08 | 38.01 |
| 2026-05-06 | IBRX | -0.08 | 6.08 | 38.01 |
| 2026-05-07 | IBRX | -0.08 | 6.08 | 38.01 |
| 2026-05-08 | IBRX | -0.08 | 6.08 | 38.01 |
| 2026-05-11 | IBRX | -0.07 | 6.31 | 37.31 |
| 2026-05-12 | IBRX | -0.07 | 6.31 | 36.72 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.09
Avg. EPS Est. Current Quarter
-0.06
Avg. EPS Est. Next Quarter
-0.06
Insider Transactions
-0.07
Institutional Transactions
6.31
Beta
0.09
Average Sales Estimate Current Quarter
51
Average Sales Estimate Next Quarter
59
Fair Value
Quality Score
71
Growth Score
55
Sentiment Score
95
Actual DrawDown %
55.3
Max Drawdown 5-Year %
-92.9
Target Price
14.4
P/E
Forward P/E
PEG
P/S
60.32
P/B
P/Free Cash Flow
EPS
-0.85
Average EPS Est. Cur. Y
-0.26
EPS Next Y. (Est.)
0.15
Target Price Estimates Raised
Target Price Estimates Lowered
1
Profit Margin
-606.15
Relative Volume
0.38
Return on Equity vs Sector %
71.4
Return on Equity vs Industry %
86.9
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
478.6
◆
IBRX
Healthcare
$8.12
Swing / Pullback
Buy the dip on strong trends
WATCH
RSI
54.4
Range 1M
70.7%
Sup Dist
3.9%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-87.9%
EPS NY
92.4%
52W%
58.8%
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-3.1% upside
Upside
-3.1%
Quality
71
ImmunityBio, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 684
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
IBRX
Latest News
—
Caricamento notizie per IBRX…
stock quote shares IBRX – ImmunityBio, Inc. Stock Price stock today
news today IBRX – ImmunityBio, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch IBRX – ImmunityBio, Inc. yahoo finance google finance
stock history IBRX – ImmunityBio, Inc. invest stock market
stock prices IBRX premarket after hours
ticker IBRX fair value insiders trading